Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

Not yet recruiting

• Conditions: Placenta Previa

• Registration Number: NCT06620068
• Lead Sponsor: Guangzhou Institute of Respiratory Disease

Brief Summary

This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Detailed Description

Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-09-24
• Study Start: 2024-09-25
• Study First Submitted QC: 2024-09-26
• Last Update Submitted: 2024-09-26
• Study First Posted: 2024-10-01
• Last Update Posted: 2024-10-01
• Primary Completion: 2024-11-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 207473

Inclusion Criteria

• Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

Exclusion Criteria

• Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Causal relationship between plasma VEGFA levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Secondary Outcome Measures

Name	Time	Method
Causal relationship between plasma VEGFB levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Causal relationship between plasma VEGFC levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Causal relationship between plasma PLGF levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.